Scotland gets dapagliflozin go-ahead

People with Type 2 diabetes in Scotland have access to a new drug after physicians were given the go ahead by the Scottish Medicines Consortium (SMC) to prescribe Forxiga (dapagliflozin). The drug will be available for adults with type 2 diabetes for restricted use as dual therapy in combination with metformin, when metformin alone with diet and exercise does not provide adequate glycaemic control and a sulphonylurea is inappropriate.

Dapagliflozin is the first in a new class of treatments called sodium-glucose cotransporter 2 (SGLT2) inhibitors and developed from phlorizin, a naturally occurring sugar compound found in the bark of apple trees. It works by reducing the amount of glucose reabsorbed in the kidney. As a result, in people with Type 2 diabetes, an increased amount of glucose is passed out of the body via the urine each day, along with the associated calories.

Unlike many other diabetes medications, dapagliflozin works in a way that is independent of insulin action and offers an alternative new approach for people with type 2 diabetes currently failing with their diet, exercise plan and are uncontrolled on their existing medication.

Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).
Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags